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Walnut polyphenol metabolites, urolithins A and B,
inhibit the expression of the prostate-speciﬁc
antigen and the androgen receptor in prostate
cancer cells
Claudia Sánchez-González,a Carlos J. Ciudad,b Véronique Noéb and
Maria Izquierdo-Pulido*a,c
Walnuts have been gathering attention for their health-promoting properties. They are rich in poly-
phenols, mainly ellagitannins (ETs) that after consumption are hydrolyzed to release ellagic acid (EA). EA is
further metabolized by microbiota to form urolithins, such as A and B, which are absorbed. ETs, EA and
urolithins have shown to slow the proliferation and growth of diﬀerent types of cancer cells but the
mechanisms remain unclear. We investigate the role of urolithins in the regulatory mechanisms in prostate
cancer, speciﬁcally those related to the androgen receptor (AR), which have been linked to the develop-
ment of this type of cancer. In our study, urolithins down-regulated the mRNA and protein levels of both
prostate speciﬁc antigen (PSA) and AR in LNCaP cells. The luciferase assay performed with a construct
containing three androgen response elements (AREs) showed that urolithins inhibit AR-mediated PSA
expression at the transcriptional level. Electrophoretic mobility shift assays revealed that urolithins
decreased AR binding to its consensus response element. Additionally, urolithins induced apoptosis in
LNCaP cells, and this eﬀect correlated with a decrease in Bcl-2 protein levels. In summary, urolithins
attenuate the function of the AR by repressing its expression, causing a down-regulation of PSA levels and
inducing apoptosis. Our results suggest that a diet rich in ET-containing foods, such as walnuts, could
contribute to the prevention of prostate cancer.
1. Introduction
Prostate cancer is the second most frequently diagnosed
cancer and the sixth leading cause of cancer death among
men. Generally, the highest rates are recorded in North
America, Oceania, and Northern and Western Europe.1 Epide-
miology supports the important role of nutrition in prostate
cancer prevention.2 A number of protective compounds have
been identified in the diet, including selenium, sulforane
from cruciferous, carotenoids, and polyphenols. These food
phytochemicals may aﬀect the biological process of cancer
development via diﬀerent mechanisms. In vitro and in vivo
evidence has pointed out that phytochemicals aﬀect a broad
range of intracellular molecular targets.3–7 In particular, poly-
phenols may exert anticancer eﬀects by several mechanisms
such as reducing the pro-oxidative eﬀect of carcinogenic
agents,8,9 modulation of cancer cell signaling,10,11 cell cycle
progression,12,13 promotion of apoptosis,14,15 and modulation
of enzymatic activities.16 Regarding prostate cancer pro-
gression, a recent clinical trial assessed the eﬀect of a poly-
phenol-blend dietary supplement over prostate-specific antigen
(PSA) levels in men with localized prostate carcinoma; this
study found a significant favorable eﬀect on the percentage
rise in PSA levels, an important indicator of prostate cancer
progression.17 Polyphenols have also been shown to act on
multiple targets in pathways not only related to cancer pro-
gression, cellular proliferation and death,18 but also in inflam-
mation,19 angiogenesis,20 and drug and radiation resistance.21
Walnuts ( Juglans regia L.) have been gathering increasing
attention for their health-promoting properties, which have
been reported to improve lifestyle-related diseases such as
arteriosclerosis, hypercholesterolemia, hypertriglyceridemia,
cardiovascular disease, diabetes, and cancer.22–24 Walnuts are
rich in bioactive polyphenols (total contents ranging from
1575 mg to 2500 mg per 100 g) and they represent, on a
serving size basis, the seventh largest source of total poly-
phenols among common foods and beverages.25 The most
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abundant polyphenols in walnuts are ellagitannins (ETs),
mainly pedunculagin.26 ETs are tannins that release ellagic
acid (EA) upon hydrolysis, which are further metabolized by
gut flora to form urolithins, mainly urolithins A and B.27
These urolithins circulate in blood and can reach many of the
target organs where the eﬀects of ellagitannins are noted.27,28
Although the occurrence of ETs and EA in the bloodstream is
almost negligible, urolithins can reach a concentration at
micromolar levels in plasma,29 their maximum concentration
is reached 24 to 48 hours after consumption of ET-rich foods,
although urolithins can be found in plasma and urine up to
72 hours after consumption in both free and conjugated
forms;27 urolithins and their conjugates have also been found
in the human prostate after walnut and pomegranate juice
consumption.30 Like other polyphenols, ETs, EA and their
derived metabolites possess a wide range of biological activi-
ties which suggest that they could have beneficial eﬀects on
human health.31 Moreover, ETs and EA seem to exhibit anti-
cancer properties in vitro and in vivo. Recent research in vitro
has shown that walnut extracts have dose-dependent inhibitory
eﬀects on colon cancer cell growth32 and it has been observed
that walnuts delay the growth rate of breast cancer cells33 and
prostate cancer cells30 implanted in mice. ET-rich herbal
extracts have been shown to inhibit LNCaP cell proliferation
and reduce PSA secretion.34 Other authors have also attributed
estrogenic and anti-estrogenic activity to urolithins based on
their binding aﬃnity to the estrogen receptor in MCF-7 cells,
labeling urolithins as potential endocrine-disruptive molecules.29
Prostate-specific antigen is a well-known prostate tumor
marker, expressed at a high level in the luminal epithelial cells
of the prostate and is absent or expressed at very low levels in
other tissues.35 However recent data suggest that PSA is not
only a biomarker, but that it also has a biological role in the
development and progression of prostate cancer, since it is
involved in tumor growth, invasion and metastasis.36 PSA is
encoded by the KLK3 gene and its expression is tightly con-
trolled by androgen through the action of the androgen recep-
tor (AR).37 Upon binding to androgen, AR translocates into the
nucleus and binds to the androgen response elements (AREs)
on the PSA promoter, interacting with other transcription
factors and activating PSA gene transcription.38 The expression
of PSA in prostate cancer generally reflects the transcriptional
activity of AR, but additional factors regulating the PSA promo-
ter have also been identified.39–41
Considering all of the above, we hypothesized that the
main walnut polyphenol metabolites, urolithins A and B,
could exert a role over regulatory mechanisms in prostate
cancer, specifically those related to the androgen receptor,
which have been linked to the development and progression of
this type of cancer. To this purpose, and using a prostate
cancer cell model (LNCaP cells), we investigated the eﬀects of
urolithins A and B on the gene expression of PSA and AR and
their protein expression. We also assayed the ability of those
compounds to modify the PSA promoter activity and to bind
AR. In addition, the eﬀect of both urolithins on apoptosis was
also explored.
2. Experimental
2.1 Materials and chemicals
Urolithin A (UA; 3,8-dihydroxy-6H-dibenzo[b,d]pyran-6-one,
95% purity) and urolithin B (UB; 3-dihydroxy-6H-dibenzo[b,d]-
pyran-6-one, 98% purity) were synthesized by the Department
of Organic Chemistry, School of Pharmacy at the University of
Barcelona (Barcelona, Spain). Urolithins and dehydrotesto-
sterone (DHT) (Sigma-Aldrich, Madrid, Spain) were suspended
in DMSO.
2.2 Cell culture
LNCaP (androgen responsive) and PC3 (androgen indepen-
dent) human prostate adenocarcinoma cell lines were routinely
grown in Ham’s F-12 medium, supplemented with 7% (v/v)
fetal bovine serum (FBS, both from GIBCO, Invitrogen, Barce-
lona, Spain), sodium penicillin G and streptomycin, and were
maintained at 37 °C under a humidified atmosphere contain-
ing 5% CO2. 250 000–500 000 cells were incubated with 40 μM
of either urolithin A or urolithin B, or a combination com-
posed of 20 μM UA and 20 μM UB (named MIX). This concen-
tration was chosen because it can be found in plasma after
consumption of ET-rich foods,26–28 and it is within the range
used to assay the biological activity of urolithins.42,43
In addition, this concentration was not cytotoxic (data not
shown). Incubations were also performed, depending upon the
experiment, with 1 nM of DHT. The final concentration of
DMSO in the culture medium was always ≤0.5%.
2.3 RT-real time PCR
Total RNA was extracted from LNCaP using the Trizol reagent
(Life Technologies, Madrid, Spain) in accordance with the
manufacturer’s instructions. Complementary DNA (cDNA) was
synthesized as described by Oleaga et al. (2013).44 RNA concen-
tration and purity was checked using a Nanodrop spectro-
photometer system (ND-1000 3·3 Nanodrop Technologies,
Wilmington, DE, USA). mRNA levels were determined with Ste-
pOnePlus™ real-time PCR systems (Applied Biosystems, Barce-
lona, Spain) using 3 μL of cDNA and Taqman probes (Applied
Biosystems, Barcelona, Spain), for KLK3 (Hs02576345) and AR
(Hs00171172) genes and APRT (Hs00975725) as an endogenous
control. Changes in gene expression were calculated using the
quantitative ΔΔCt method and normalized against APRT in
each sample.
2.4 Western blot
LNCaP cells (350 000) were plated on 35 mm dishes and
treated the day after with the diﬀerent compounds. Twenty-
four hours after incubation cells were collected and centri-
fuged for 5 min at 800g at 4 °C. The cell pellets were sus-
pended in 200 μL of lysis buﬀer (0.5 M NaCl, 1.5 mM MgCl2,
1 mM EGTA, 10% glycerol 1% Triton x_100, 50 mM HEPES,
pH 7.9 all from Applichem, Barcelona, Spain), and 10 μL pro-
tease inhibitor cocktail (from Sigma-Aldrich, Madrid, Spain).
The cell lysate was kept on ice for 60 min vortexing every
15 min. Cellular debris was removed by centrifugation at
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15 000g at 4 °C for 10 min. A 5 μL aliquot of the extract was
used to determine the protein concentration using the Brad-
ford assay (Bio-Rad, Barcelona, Spain).
Whole cell extracts (100 μg) were resolved in 12% SDS-poly-
acrylamide gels and transferred to PVDF membranes (Immobi-
lon P, Millipore, Madrid, Spain) using a semidry electroblotter.
Membranes were probed overnight at 4 °C with primary anti-
bodies against AR (1 : 200 dilution; sc-816 from Santa-Cruz Bio-
technology Inc., Heidelberg, Germany), PSA (1 : 300 dilution;
A0562 from Dako, Denmark) or Bcl-2 (1 : 200 dilution; sc-492
from Santa-Cruz Biotechnology Inc., Heidelberg, Germany).
Signals were detected by secondary horseradish peroxidase-
conjugated antibody, either anti-rabbit (1 : 2500; Dako,
Denmark) or anti-mouse (1 : 2500 dilution, sc-2005 Santa Cruz
Biotechnology Inc., Heidelberg, Germany) and enhanced che-
miluminescence using the ECL™ Prime Western blotting
detection reagent, as recommended by the manufacturer (GE
Healthcare, Barcelona, Spain). Chemiluminescence was
detected with ImageQuant LAS 4000 Mini technology (GE
Healthcare, Barcelona, Spain). Normalization of the blots was
performed by incubation with an antibody against tubulin
(1 : 800 dilution, sc-5286 from Santa-Cruz Biotechnology Inc.,
Heidelberg, Germany).
2.5 Transfection and luciferase assay
PC3 cells (350 000) were plated in 35 mm dishes the day before
transfection. The medium (2 ml) was renewed before transfec-
tion, which was performed using FuGENE 6 (Roche, Barcelona,
Spain). For each well, the transfection reagent was incubated
for 5 minutes in 100 μL of antibiotic and serum free medium,
followed by the addition of plasmid DNA and incubated for
another 20 min at a ratio of 3 : 1 (μL of transfection reagent : μg
of plasmid DNA). One μg of plasmid DNA, either pGL3 basic
vector or PSAp, a 6 kb PSA promoter construct containing
three AREs in front of a luciferase reporter gene were used for
transfection.
Incubation with 40 μM of UA, UB or MIX and 1 nM of DHT
was performed 6 hours after transfection, and the luciferase
activity was determined 24 hours after transfection. Cell
extracts were prepared by lysing cells with 100 μL of reporter
lysis buﬀer (2 mM DTT, 2 mM EDTA, 10% glycerol, 1% Triton
X_100, 25 mM Tris-phosphate, pH 7.8). The lysate was centri-
fuged at 12 000g for 2 min at 4 °C to pellet cell debris and
supernatants were transferred to a fresh tube. Fifteen μL of the
extract were added to 15 μL of the luciferase assay substrate
(Promega, Madrid, Spain) at room temperature. Luminescence
was measured using the Glomax™ 20/20 luminometer
(Promega, Madrid, Spain) and expressed as relative lumine-
scence units (RLU). Luciferase results were normalized by the
total protein concentration in the cell lysates. Protein concen-
tration was determined by the Bradford assay (Bio-Rad, Barce-
lona, Spain) according to the manufacturer’s protocol.
2.6 Nuclear extracts
Nuclear extracts were prepared according to the protocol
described by Andrews and Faller (1991).45 Briefly, 500 000 cells
were plated and incubated the following day with urolithins A,
B or MIX and 1 nM DHT. Cells were collected in cold PBS after
being treated for 24 hours. Cells were pelleted and suspended
in a cold hypotonic buﬀer (1.5 mM MgCl2, 10 mM KCl (Appli-
Chem, Barcelona, Spain), 0.5 mM DTT, 0.2 mM PMSF, 10 mM
HEPES-KOH, pH 8.0 from Sigma-Aldrich, Madrid, Spain). Cells
were then allowed to swell for 10 minutes, vortexed and pel-
leted by centrifugation. The resulting pellet was then sus-
pended in a cold high-salt buﬀer (25% glycerol, 420 mM NaCl,
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT, 0.2 mM PMSF,
20 mM HEPES-KOH, pH 8.0) for 20 minutes. Cellular debris
was removed by centrifugation and the supernatant fraction
was stored at −80 °C until further use.
2.7 Electrophoretic mobility shift assay
EMSA assay was performed using LNCaP nuclear extracts pre-
pared as previously described. AR consensus double-stranded
oligonucleotide 5′-CTA GAA GTC TGG TAC AGG GTG TTC TTT
TTG CA-3′ (binding site in bold) was obtained from Santa Cruz
Biotechnology, Heidelberg, Germany (sc-2551). One hundred
nanograms of the AR consensus sequence was 5′-end-labeled
with T4 polynucleotide kinase (New England Biolabs, Beverly,
MA) and [γ-32P]ATP (3000 Ci mmol−1, Perkin Elmer, Madrid,
Spain) as described by Rodríguez et al. (2013).46
The radiolabeled probe (20 000 cpm) was incubated in a
20 μL reaction mixture also containing 1 μg of Herring sperm
DNA (Invitrogen, Barcelona, Spain) as an unspecific competi-
tor, 2 μg of nuclear extract protein, 5% glycerol, 4 mM MgCI2,
60 mM KCl and 25 mM Tris-HCl, pH 8.0 (AppliChem, Barce-
lona, Spain). Samples were resolved by gel electrophoresis (5%
polyacrylamide, 5% glycerol, 1 mM EDTA and 45 mM Tris-
borate, pH 8.0; AppliChem, Barcelona, Spain). The gel was
dried for 90 minutes, exposed to europium plates overnight
and analyzed using a Storm 840 Phosphorimager (Molecular
Dynamics, GE Healthcare Life Sciences, Barcelona, Spain).
To determine the binding specificity, the radiolabeled ARE
probe was competed either with 3 ng (5-fold) of unlabeled ARE
consensus or a mutant ARE oligonucleotide. The mutant AR
oligonucleotide had two “GT” to “CA” substitutions in the AR
binding motif 5′-CTA GAA GTC TGC CAC AGG GTC ATC TTT
TTG CA-3′ (binding site in bold) (sc-2552, Santa Cruz
Biotechnology, Heidelberg, Germany). These experiments
were performed using NE from LNCaP cells treated with 1 nM
DHT.
2.8 Apoptosis
Apoptosis was determined by the rhodamine method. LNCaP
cells (250 000) were plated in 35 mm dishes with 2 ml com-
plete F-12 medium and after 24 h, they were treated with
40 μM UA, UB or MIX. Staurosporine (1 μM) (Sigma-Aldrich,
Madrid, Spain) was used as a positive control. Rhodamine
(final concentration 5 ng ml−1) (Sigma-Aldrich, Madrid, Spain)
was added for 30 min and the cells were collected, centrifuged
at 800g at 4 °C for 5 min, and washed once with PBS. The
pellet was suspended in 500 ml PBS plus propidium iodide
(PI) (final concentration 5 mg ml−1) (Sigma-Aldrich, Madrid,
Paper Food & Function
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Spain). Flow cytometry data were analyzed using the Summit
v4.3 software. The percentage of Rho-negative, PI negative cells
corresponds to the apoptotic population.
2.9 Statistical analyses
All data are reported as mean ± SE and are representative of at
least three independent experiments. Data were analyzed
using one-way ANOVA followed by the Bonferroni post hoc
multiple range test using the SPSS software v.21. The diﬀer-
ence between groups was considered statistically significant at
p < 0.05.
3. Results
3.1 Urolithins A and B decrease PSA mRNA and protein
levels in LNCaP cells
Taking into account the role of prostate specific antigen in
prostate cancer, we analyzed the eﬀect of urolithins on PSA
mRNA expression. LNCaP cells were incubated with urolithins
during diﬀerent time periods (12, 24, and 48 h). Total RNA was
extracted and PSA expression was analyzed by RT-real time
PCR (Fig. 1A). On average, urolithins induced the major
decrease in PSA mRNA levels after 24 hours; urolithin A pro-
voked an 85% reduction, a similar eﬀect was observed after
incubation with MIX at the same time point, while UB exerted
a 50% inhibition. To examine whether the eﬀects observed at
the mRNA level were translated into the protein, we performed
Western blot analyses in LNCaP cells after 24 hour incubation
with urolithins. As shown in Fig. 1B, cells incubated with UA
exhibited a 63% decrease in PSA protein levels compared
to the untreated control, followed by cells treated with MIX
or UB.
3.2 Urolithins A and B decrease AR mRNA and protein
expression
To determine whether urolithins were able to modulate AR
mRNA expression, LNCaP cells were incubated for several time
periods, between 9 and 24 hours; total RNA was extracted and
AR expression was analyzed by RT-real time PCR. A decrease in
AR mRNA levels was observed at every time point (Fig. 2A).
The major decrease was observed after the incubation with UA
and MIX, obtaining on average a reduction of 60% for both
9 and 12 hours. Androgen receptor protein levels were also
determined in LNCaP cells treated with urolithins, inducing a
decrease between 50% and 60% (Fig. 2B).
3.3 Urolithins A and B inhibit the PSA promoter activity
To assess whether urolithins aﬀected the transcriptional acti-
vation of PSA, transient transfections in PC3 cells using a luci-
ferase reporter vector carrying 6 kb of the PSA promoter were
performed.47 PC3 cells were chosen because they are PSA nega-
tive and although they are considered AR-negative they do
express low AR mRNA and protein levels48 in addition to retain-
ing co-regulators necessary for AR activity in prostate tumor pro-
gression.49 Therefore, changes in PSA promoter activity would
be accurately reflected after incubation with urolithins and/or
DHT in these reporter assays. Six hours after transfection with
the reporter vector, cells were incubated with urolithins, either
in the absence or in the presence of DHT. As expected, treatment
with 1 nM DHT increased the luciferase activity by 83% com-
pared to cells incubated in the absence of DHT, which exhibited
similar activity to the basic pGL3 vector (Fig. 3). DHT-incubated
cells treated with UA, UB or MIX showed a reduction in lucifer-
ase activity. UA-incubated cells showed a slightly higher inhi-
bition in luciferase activity than UB and MIX when compared to
the DHT-induced promoter, although this was not statistically
Fig. 1 (A) PSA mRNA levels determined by real time RT-PCR. Bars represent PSA mRNA levels in LNCaP cells either control (0.10% of DMSO) or
incubated with UA, UB or MIX. The diﬀerent incubation conditions are indicated in the ﬁgure. Results are expressed in fold changes compared to the
untreated cells and normalized using APRT as an endogenous control. They are the mean ± SE of 3 diﬀerent experiments. ***p < 0.001. (B) Determi-
nation of PSA protein levels by Western blotting. Bars represent PSA protein levels in LNCaP cells either control (0.10% of DMSO) or incubated with
UA, UB or MIX. Results are expressed in fold changes compared to the untreated cells and represent the mean ± SE of 3 diﬀerent experiments. ***p
< 0.001.
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significant (Fig. 3). These results indicated a repression of DHT-
induced PSA promoter activation by urolithins. Cells incubated
only with UA, UB or MIX exhibited basal luciferase activity,
similar to the activity observed for pGL3 and PSAp in the
absence of DHT (inactive PSAp, data not shown).
3.4 PSA expression correlates with the binding of nuclear
extracts to an ARE
The regulation of PSA by androgens takes place through
the ARE sequences in its promoter region.38 The eﬀect of
Fig. 2 (A) AR mRNA levels determined by real time RT-PCR. Incubation conditions are the same as described in Fig. 1A. Results are expressed in fold
changes compared to the untreated cells and normalized using APRT as an endogenous control. They are the mean ± SE of 3 diﬀerent experiments.
***p < 0.001. (B) Determination of AR protein levels by Western blotting. Results are expressed in fold changes compared to the untreated cells and
represent the mean ± SE of 3 diﬀerent experiments. ***p < 0.001.
Fig. 3 PSA promoter activity in PC3 cells. Cells were transfected with a
luciferase reporter vector carrying 6 kb of the PSA promoter, and 6 h
later they were treated with UA, UB and MIX in the presence or absence
of 1 nM DHT. Results are expressed as luciferase relative units/total
protein compared to control. They are the mean ± SE of 3 diﬀerent
experiments. ***p < 0.001. N.S., not signiﬁcant. Fig. 4 (A) Eﬀect of urolithins on AR binding to nuclear proteins. EMSA
was performed using the AR consensus sequence as a probe and
nuclear extracts from LNCaP cells. First lane corresponds to the probe
alone. Nuclear extracts were either control or treated cells with 1 nM
DHT and 40 μM of UA, UB or MIX for 24 hours. ***p < 0.001. N.S., not
signiﬁcant. (B) Competition assays. The binding of untreated LNCaP
nuclear extracts to the AR consensus sequence was competed with the
addition of either 3 ng (5-fold excess) of unlabeled AR or unlabeled
mutated AR in the binding reaction.
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urolithins on ARE binding to nuclear proteins was determined
using electrophoretic mobility shift assays (EMSAs). EMSAs
were performed using an ARE consensus sequence as the
probe and nuclear extracts from untreated (control) and
treated LNCaP cells. Cells were incubated with 1 nM DHT and
urolithins for 24 hours. As shown in Fig. 4A, the interaction of
nuclear extracts from control cells with the radiolabelled probe
originated a shifted band, the intensity of which was clearly
decreased upon incubation with UA, UB or MIX. The highest
reduction was seen after UA and MIX incubation (Fig. 4A),
with an 85% decrease in band intensity, followed by UB.
To assess the binding specificity, 3 ng of unlabeled consen-
sus ARE (corresponding to a 5-fold excess compared to the
probe) or unlabeled mutated AR were added to the binding
reaction. As shown in Fig. 4B, a 56% reduction in band inten-
sity was observed when the binding to the ARE labeled probe
was competed with the unlabeled probe, whereas the compe-
tition with the unlabeled mutated AR did not aﬀect the inten-
sity of the shifted band.
3.5 Urolithins A and B induce apoptosis and a decrease of
Bcl-2 protein levels in LNCaP cells
We examined the eﬀect of urolithins on apoptosis using the
rhodamine method. Following incubation of LNCaP cells with
UA, UB and MIX for 24 hours, the percentage of apoptotic cells
increased compared with the control (0.20% DMSO). A 14%
increase in apoptotic cell population was observed after incu-
bation with UA, whereas UB and MIX caused a 7% increase,
although this diﬀerence was not statistically significant
(Fig. 5A–5C). Both in vitro and in vivo studies have established
that Bcl-2 expression confers anti-apoptotic activity in prostate
cancer and its overexpression is linked to progression into
advanced prostate cancer.50 Bcl-2 overexpression has also been
correlated with high PSA levels in prostate cancer.36 Hence,
Bcl-2 protein levels were measured after urolithin incubation.
UA, UB and MIX induced a decrease in Bcl-2 protein levels
after 24 hour treatment (Fig. 5D).
4. Discussion
The main objective of our study was to determine the potential
role of the major polyphenol metabolites in walnuts, uro-
lithins, in the modulation of the prostate-specific antigen and
the androgen receptor in prostate cancer cells. A great number
of dietary components such as lycopene, vitamin E, selenium,
isoflavones and polyphenols potentially aﬀect a range of carci-
nogenic pathways in the prostate, including androgen meta-
bolism, cell cycle processes and apoptosis, maintenance of
mitochondrial membrane potentials, insulin-like growth factor
Fig. 5 Apoptosis determined by ﬂow cytometry. (A) Representative ﬂow cytometer histograms displaying the cell population in the untreated
control sample (0.12% DMSO) and (B) in cells incubated with 40 μM UA. (C) Percentage of apoptotic cells determined by ﬂow cytometry. Bars rep-
resent LNCaP cells either untreated control (0.12% of DMSO), or incubated with UA, UB or MIX (40 μM) after 24 hour of exposure. Results represent
the mean ± SE of 3 diﬀerent experiments. *p < 0.05. (D) Bcl-2 protein levels in cells incubated with UA, UB or MIX for 24 hours. ***p < 0.001.
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(IGF)-Akt signaling, and response to oxidative stress.51
Although, these dietary components have been assessed for
their chemo-preventive capacities, there are a limited number
of studies focusing on the role that walnut polyphenols have in
the prevention of prostate cancer, especially those addressed
to elucidate the molecular mechanisms involved. As an
example, the anticancer activity for urolithins A, B, C, and D
through the inhibition of CYP1B152 was reported in human
prostate carcinoma 22Rv1 cells, while pedunculagin,30 ellagic
acid42 and extracts from the green husk of walnuts53 showed
an anti-proliferative and apoptotic eﬀect on LNCaP cells. Other
authors have also observed that urolithins localized to the
mouse prostate gland and inhibited the growth of both andro-
gen-dependent and androgen-independent prostate cancer cell
lines.54
In our study, there was a clear repression of PSA transcrip-
tion by urolithins A and B, as well as a decrease in PSA protein
levels. The aforementioned decrease in PSA levels upon treat-
ment with urolithins correlated with the down-regulation of
the androgen receptor. The decrease in PSA and AR levels after
incubation with urolithins is in agreement with the eﬀects
reported for other phenolic compounds, such as epigallocate-
chin gallate (EGCG), grape seed procyanidins or caﬀeic acid.
PSA and AR play a pivotal role in prostate cancer development
and progression and a potential cross-talk between these two
genes has been postulated by several authors.55,56 In a recent
study, Saxena et al. (2012)55 pointed out that PSA is not only a
biomarker of prostate cancer and a known downstream target
of the androgen receptor, but it is also required for AR mRNA
and protein expression. Similarly, several authors reported that
AR inhibition resulted in a marked decrease in cell prolifer-
ation.57,58 Thus, the observed eﬀect of urolithins on prostate
cancer cells could be due to their possible interference in this
cross-talk and the reduction of PSA and AR levels.
A possible manner by which urolithins could interfere with
the previously mentioned AR-PSA cross-talk is by displaying
phytoestrogen-like activity. In this direction, the modulation of
hormone receptors by phenolic dietary components, such as
isoflavones, has been widely studied. Some authors compared
urolithins with several phytoestrogens, such as genistein, daid-
zein, resveratrol and enterolactone. These authors reported an
interference caused by urolithins in endocrine pathways pro-
posing them as possible phytoestrogens.29 In this sense, the
estrogenic and anti-estrogenic activity reported for urolithins
has been related to their interaction with the estrogen receptor
in human breast cancer cells (MCF-7).29 However, phytoestro-
gens, such as genistein, do not only interact with the estrogen
receptor but have also been shown to decrease AR levels in
LNCaP cells, and to cause a reduction in the binding of
nuclear proteins to an ARE.59 Considering all of the above, we
explored if urolithins were able to exert an eﬀect over the
androgen receptor, similar to that induced by phytoestrogens.
In our study we demonstrate that the activation of the PSA pro-
moter by DHT was blocked upon incubation with urolithins.
The reduced activation of PSA, which is an AR-regulated pro-
moter, could be explained by the decrease in the binding of
nuclear proteins to a consensus ARE, which under our con-
ditions was an 86% reduction. In addition, the binding of AR
to AREs was reduced by 32% after direct incubation of
untreated nuclear proteins with UA (data not shown). Hence,
the decrease in transcription caused by urolithins over PSA
levels was due to a direct eﬀect on the PSA promoter. Our
results are in keeping with those observed by Larrosa
(2006)28,29 and colleagues who studied the binding aﬃnity of
urolithins to the estrogen receptor in breast adenocarcinoma
cells. These authors observed a higher binding aﬃnity for uro-
lithin A than for urolithin B, similar to our results in which a
higher decrease in binding was observed upon incubation
with UA when compared to UB.
It is important to note that PSA is fundamental in the
pathophysiology of prostate cancer. It stimulates oxidative
stress in LNCaP and PC3 cells,60 and is also involved in tumor
invasion and metastasis.61 Considering its role in prostate
cancer progression, we explored if the pronounced decrease of
PSA levels upon urolithin incubation would result in an
increase in apoptosis. Urolithins indeed caused an increase in
apoptotic activity in LNCaP cells. Moreover, the increase in
apoptosis upon incubation with urolithins was correlated with
a decrease in the expression of Bcl-2, a critical regulator of the
apoptotic pathway, and a potent suppressor of apoptosis.62
Human tumors usually express high levels of Bcl-2 protein and
in prostate cancer its levels correlate with high levels of PSA.36
Thus, the decrease in Bcl-2 and the apoptotic activity induced
upon incubation with urolithins could be linked to the inhi-
bition of PSA by these compounds. Other authors have
reported that juglone, a non-polyphenolic compound found in
roots and leaves of the walnut tree, can cause apoptosis in
prostate cancer cells, in this case, associated with mitochon-
drial dysfunction and activation of caspases 3 and 9.63
5. Conclusion
Our results provide new insights into the eﬀect metabolites of
a common dietary component have on molecular mechanisms
involved in prostate carcinogenesis, which could in turn
provide a foundation for developing strategies for disease pre-
vention. The eﬀect of dietary agents on cancer can be used to
identify molecular therapeutic targets, and used as part of a
chemo-preventive strategy. Dietary intervention targeting mul-
tiple pathways might, therefore, be an eﬀective therapeutic
approach, either alone, or in conjunction with targeted
pharmaceutical agents.
In summary, we demonstrated a reduction in PSA and AR
levels induced by urolithins. This eﬀect could be due to a
decreased binding of the AR to AREs, and to decreased levels
of the androgen receptor resulting in PSA transcription inhi-
bition. An induction of apoptosis in LNCaP cells was also
observed, which may be caused by the down-regulation of AR
and PSA, as well as a decrease of Bcl-2 protein levels. A diet
high in ET-rich foods, such as walnuts, provides a considerable
Paper Food & Function
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intake of pedunculagin and its metabolites, urolithins, which
could assist in the prevention of prostate cancer in men.
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